Technology | November 02, 2009

Xoft Installs Brachytherapy for Breast, Endometrial Cancers at UCLA

November 2, 2009 - Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, is showcasing its growing suite of oncology treatment technologies here at the 51st American Society for Radiology and Oncology (ASTRO) Meeting, November 1-5.

Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent System is also FDA-cleared for the treatment of other cancers or conditions where radiation therapy is indicated, including IORT (intra-operative radiation therapy).
Xoft also announced that Axxent eBx Systems have been installed recently at several luminary accounts, including UCLA Medical Center, Memorial Sloan Kettering Cancer Center, and Beth Israel Medical Center. The systems are currently being used to clinically treat patients for breast, endometrial and skin cancer, and will also be used for clinical studies investigating additional IORT applications.
As a platform technology, the Axxent System addresses a variety of oncological and non-oncological indications. Designed to deliver non-isotopic therapy directly to cancer sites during or following surgical removal, the Axxent System utilizes a proprietary miniaturized X-ray source and robotic controller and can be used to deliver radiation in minimally shielded therapeutic settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery which minimizes patient anxiety.

For more information: www.xoftinc.com

Related Content

Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
Isoray to Spotlight Cesium-131 Advances at ASTRO Annual Meeting
News | Brachytherapy Systems | September 13, 2019
Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131 brachytherapy at the...
The Zap-X stereotactic radiosurgery (SRS) brain radiotherapy system is completely self-shielded, eliminating the need for a concrete vault. The goal of the system is to expand SRS brain therapy by making it easier to access and less expensive by eliminating the large expense of custom built vaults to house the system. #AAPM19 #AAPM2019 #AAPM

The Zap-X stereotactic radiosurgery (SRS) brain radiotherapy system is completely self-shielded, eliminating the need for a concrete vault. The goal of the system is to expand SRS brain therapy by making it easier to access and less expensive by eliminating the large expense of custom-built vaults to house the system. 

Feature | AAPM | August 21, 2019 | Dave Fornell, Editor
There were several trends and new technologies in radiation oncology discussed at the ...
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
Varian Showcases Cancer Care Systems and Software at AAPM 2019
News | Radiation Therapy | August 02, 2019
Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Videos | Radiation Therapy | February 21, 2019
ITN Associate Editor Jeff Zagoudis speaks with...